News

Public · Published

Theriva Biologics, Inc. (TOVX) Sells Portfolio for $350.0K Upfront, Plus Potential Milestones

Theriva Biologics sold its antibiotic-degrading enzyme portfolio to Biossil for $350.0K upfront. The deal also provides for up to $3M in regulatory milestones, up to $88M in sales milestones, and low single-digit royalties capped at $250M. Biossil assumes future development and commercialization costs.

Published:

Updated:

What happened

Theriva Biologics sold its antibiotic-degrading enzyme portfolio to Biossil for $350.0K upfront. The deal also provides for up to $3M in regulatory milestones, up to $88M in sales milestones, and low single-digit royalties capped at $250M. Biossil assumes future development and commercialization costs.

Confirmed

Global impact / market context

Theriva receives $350.0K at closing, while most additional value depends on Biossil advancing the portfolio, meeting regulatory milestones, and generating sales. Shifting future development costs to Biossil may reduce Theriva’s spending burden, but the contingent payments are not assured.

Analyst inference

The article identifies VCN-01 as Theriva’s lead product candidate but gives no prior-period comparison or market reaction. The sale concerns a separate enzyme portfolio, so its financial effect depends on whether contingent payments eventually outweigh the upfront cash and reduced costs.

Analyst inference

What to watch

  1. Whether Biossil advances the portfolio through development and achieves the regulatory milestones required for Theriva to receive up to $3M in additional payments. Analyst inference
  2. Whether future product sales reach the cumulative worldwide net-sales thresholds tied to up to $88M in sales milestones and low single-digit royalties. Analyst inference
  3. How the royalty cap of $250M applies to future net product sales, since the article does not specify timing or detailed payment terms. Confirmed

Evidence